Akari Therapeutics PLC (AKTX NASDAQ) stock market data APIs
$1.1383
-0(-0%)
as of July 11, 2025
Try our APIs with
free plan!
Akari Therapeutics PLC Financial Data Overview
Price chart is built with
Anychart
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR) and DNA damage response (DDR) to generate neoepitopes, and PH6, which inhibits DNA transcription in cancer cells and co-opted immune cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Boston, Massachusetts.
Prev. Close
1.1383
Open
1.1369
High
1.1446
Low
1.1112
52 wk Range
0.85-4.4
Market Cap
36 382 K
P/E Ratio
0
Shares Outstanding
32 176 K
EPS
-0.19
Beta
0.247
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Akari Therapeutics PLC data using free add-ons & libraries
Get Akari Therapeutics PLC Fundamental Data
Akari Therapeutics PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -14 178 500
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-04-15
- EPS/Forecast: -1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Akari Therapeutics PLC News
New
Akari Therapeutics shareholders approve equity plan increase and director elections
Akari Therapeutics Plc (NASDAQ:AKTX), a biotechnology company with a current market capitalization of $37.64 million, reported Tuesday that shareholders approved all proposals at its Annual General Me...
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
European equities traded in the US as American depositary receipts were modestly higher late Thursda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Akari Therapeutics secures Indian patent for cancer drug payload
BOSTON/LONDON - Akari Therapeutics, Plc (NASDAQ:AKTX), a micro-cap biotech company currently valued at $38 million, has been granted Patent No. 562,919 by Intellectual Property India for its PH1 paylo...
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
Differentiated PH1 payload is a spliceosome inhibitor designed to inhibit RNA splicing, leading to cancer cell death and activation of immune system through multiple mechanisms India represents a key...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
